文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > 替米沙坦对急性卒中预后复发的作用
侵权投诉

替米沙坦对急性卒中预后复发的作用

Bathetal

Table3.CumulativeOutcomeandSafetyatDays7,30,and90AfterEnrollment

Telmisartan(n 647)

7DaysDropouts(%)*Hemorrhagic

transformation(%)Cerebraledema(%)Strokerecurrence(%)MI(%)

Combinedvascular(%)Death(%)SAE(%)30DaysDropouts(%) mRS(mean,SD)mRS0–1vs2–6(%) Strokerecurrence(%)MI(%)

Combinedvascular(%)Death(%)SAE(%)

Mini-MentalStateExamination 30(%)90DaysDropouts(%)*Strokerecurrence(%)MI(%)

Combinedvascular(%)Death(%)SAE(%)

6(0.93)17(2.6)3(0.5)23(3.6)5(0.77)50(7.73)

6(0.84)14(2.0)1(0.1)19(2.7)6(0.84)39(5.47)

1.25(0.36,4.36)1.40(0.68,2.89)

…1.48(0.78,2.79)1.05(0.27,4.04)1.43(0.93,2.22)

4(0.621.3(1.1)401(64.5)13(2.01)2(0.31)17(2.63)4(0.62)29(4.48)190(32.0)

2(0.28)1.3(1.1)452(65.7)8(1.12)0(0.0)10(1.40)2(0.28)25(3.51)207(31.7)

3.98(0.52,30.2)

…1.00(0.77,1.29)1.89(0.77,4.62)

…2.07(0.93,4.63)

…1.30(0.75,2.25)1.02(0.80,1.31)

0(0.0)0(0.0)0(0.0)4(0.62)1(0.15)5(0.77)0(0.0)12(1.85)

1(0.14)3(0.42)0(0.0)5(0.70)0(0.0)6(0.84)1(0.14)10(1.40)

………0.88(0.24,3.31)

…0.95(0.28,3.16)

…1.37(0.59,3.21)

Placebo(n 713)

OR(95%CI)

TelmisartaninAcuteIschemicStroke3545

Figure2.Ordinalstroke(recurrenceandseverity)atday90,

comparisonbyMann–WhitneyUtest,P 0.42(note:themajorityofpatientswhodidnothaveaneventarenotshown,and3patientswitharecurrentstrokedidnothaveamRSrecorded;thenumbersofpatientswitheachoutcomeareshown).

N(%)ormean(SD)withOR(95%CI).Comparisonbybinarylogisticregressionormultipleregression(continuousvariables).SAEindicatesseriousadverseevents.

*Dropoutsarepatientslosttofollow-upatthetimepoint. Patientswithnoday30outcomedatawere

替米沙坦对急性卒中预后复发的作用

excluded.

havingarecurrenteventwaspresentinthosepatientswhowereenrolledduringtheacutephase.

TheresultsofthissubgroupanalysismaybecomparedwithpreviousstudiesofBP-loweringinacuteischemicstroke,especiallythosefromtheACCESStrial,15whichalsostudiedanoralARA(candesartan)inpatientswithacuteischemicstrokewithin72hoursofonset.However,thetrialsdifferedinseveralkeyrespects:size(ACCESSwasmuchsmallerwith339patients);timetorecruitment(ACCESShadameantimeof30hours);BPinclusioncriteria(ACCESSonlyincludedpatientswithseverelyelevatedBPandhadmeanBP189/99mmHg);presenceofotherantihypertensiveagents(patientsinACCESSwerenotusinganyotherBPdrugs);strokeseverity(thebaselineseverityisnotreportedintheACCESSarticlebutitislikelythatthestrokeswillhavebeenfarmoreseverewithsignificantlygreaterimpairment);location(patientsinACCESScamefromGermanyonly);lengthoftreatment(comparisonofcandesartanwithplacebo

inACCESSwasonlymadefor7dayswithpatientsinbothtreatmentgroupsreceivingcandesartanthereafterfor1year);effectoftreatmentonBP(candesartandidnotalterBPinACCESS);andresults(theprimaryoutcome,disabilityat3months,inACCESSwasneutral,althoughtreatmentwithcandesartanwasassociatedwithasignificantreductioninasecondaryoutcome,comprisingthecumulative12-monthmortalityandvascularevents).15

TakingthesimilaritiesanddifferencesbetweenACCESSandPRoFESS,theapparentdiscrepanciesintheirresultsmaysimplyreflectafalse-positivefindinginthesmallACCESStrial.Additionally,thefailuretoshowbeneficialeffectsoftelmisartanmayreflectthatpatientshadonlymildhyperten-sionandmildstroke.Nevertheless,thissubgroupanalysisofPRoFESSisthefirsttoourknowledgetotestwhetheritissafeforpatientswithacutemildstroketohavetheirBPactivelylowered.BecausechronicloweringofBPreducesstrokerecurrence,23,24thepresentresultssuggestitissafetostartsuchtreatmentacutely,particularlyifbasedonanangiotensin-modifyingdrug.Further,itispossiblethattheseresultscanbeextrapolatedtopatientswithTIAforwhichnotrialshavebeenperformedtodateand,possibly,nonearelikely.SeveralcaveatsexistforthisPRoFESSsubgroupanalysis.First,theresultscomefromasubgroupofpatientsenteredintoalargesecondarypreventiontrialsuchthatpatientcharacteristicsreflecttheinclusioncriteriaforastudyofvascularprophylaxisratherthanacuteintervention.Asaresult,thetrialwasnotdesignedtoexplicitlytesttheeffectofloweringBPinacutestroke.Second,theinclusioncriteriaincludedneurologicalstability,whichisusuallyabsentinacutestroke,andmeansthatnopatientswererecruitedduringthehyperacutephase( 6hoursofonset)ofstroke.Third,thesamplesizewastoosmalltoreliablydetecttheeffectsoftelmisartanonfunctionaloutcomeorsecondaryprevention.TheongoingSCASTtrial(doc.guandang.net)ofcandesar-tanin2500patientswillextendtheexistingdatafromACCESSandPRoFESSonloweringBPinacuteischemicstrokewithARA.OtherlargetrialsarealsoassessingthemanagementofBPinacutestroke,includingENOS

上一页第5页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email